A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
GENERAL DEVELOPMENT OF BUSINESS Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances. NARRATIVE DESCRIPTION OF BUSINESS Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 44.3B | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B |
| Net Income | 6.5B | 6.5B | 13.4B | 5.7B | 6.9B | 7.1B |
| EPS | $3.72 | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Free Cash Flow | 7.4B | 7.4B | 6.4B | 5.1B | 7.8B | 8.6B |
| ROIC | 10.4% | 10.8% | 12.3% | 11.8% | 15.3% | 16.4% |
| Gross Margin | 56.4% | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% |
| Debt/Equity | 0.31 | 0.31 | 0.33 | 0.41 | 0.52 | 0.53 |
| Dividends/Share | $2.35 | $2.40 | $2.24 | $2.03 | $1.87 | $1.78 |
| Operating Income | 8.1B | 8.1B | 6.8B | 6.5B | 8.4B | 8.4B |
| Operating Margin | 18.2% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% |
| ROE | 12.5% | 13.1% | 28.1% | 14.8% | 18.9% | 19.8% |
| Shares Outstanding | 1,754M | 1,754M | 1,754M | 1,756M | 1,773M | 1,795M |
ABBOTT LABORATORIES passes 8 of 9 quality checks, indicating strong fundamentals.
ABBOTT LABORATORIES trades at 27.2x trailing earnings, compared to its 15-year median P/E of 33.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 23.7x vs a median of 28.2x. The company's 5-year average ROIC is 13.3% with a gross margin of 56.0%. Total shareholder yield (dividends + buybacks) is 2.8%. At current prices, the estimated annualized return to fair value is +4.5%.
ABBOTT LABORATORIES (ABT) has a current P/E ratio of 27.2, compared to its historical median P/E of 33.4. The stock is currently considered Fair based on its historical valuation range.
ABBOTT LABORATORIES (ABT) has a 5-year average return on invested capital (ROIC) of 13.3%. This indicates solid capital allocation.
ABBOTT LABORATORIES (ABT) has a market capitalization of $177.2B. It is classified as a large-cap stock.
Yes, ABBOTT LABORATORIES (ABT) pays a dividend with a trailing twelve-month yield of 2.32%. The company also returns capital through share buybacks, with a buyback yield of 0.50%.
Based on historical P/E analysis, ABBOTT LABORATORIES (ABT) appears fair. The current P/E of 27.2 is 19% below its historical median of 33.4. The estimated fair value CAGR (P/E method) is 20.7%.
ABBOTT LABORATORIES (ABT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ABBOTT LABORATORIES (ABT) reported annual revenue of $44.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
ABBOTT LABORATORIES (ABT) has a net profit margin of 14.7%. This is a healthy margin.
ABBOTT LABORATORIES (ABT) generated $7.4 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ABBOTT LABORATORIES (ABT) has a debt-to-equity ratio of 0.31. This indicates a conservatively financed balance sheet.
ABBOTT LABORATORIES (ABT) reported earnings per share (EPS) of $3.72 in its most recent fiscal year.
ABBOTT LABORATORIES (ABT) has a return on equity (ROE) of 13.1%. This indicates moderate shareholder returns.
ABBOTT LABORATORIES (ABT) has a 5-year average gross margin of 56.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for ABBOTT LABORATORIES (ABT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABBOTT LABORATORIES (ABT) has a book value per share of $29.72, based on its most recent annual SEC filing.